This review demonstrates that switching from reference biologics to biosimilars maintains disease control in ankylosing spondylitis, suggesting effective implementation strategies.
Key Points
The aim is to evaluate the safety and efficacy of switching ankylosing spondylitis patients from reference biologics to biosimilars.
Synthesized evidence from regulatory programs, randomized controlled trials, and observational studies.
Conducted structured narrative review based on database searches from PubMed, EMBASE, and the Cochrane Library.
Assessed molecular similarity and therapeutic equivalence through various studies.
Switching does not compromise efficacy or safety profiles for stable ankylosing spondylitis patients.
Immunogenicity profiles are comparable between biosimilars and reference products.
Retention rates and disease activity outcomes remain consistent across different treatment options.